BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2017

View Archived Issues

New S1P1-specific PET radioligands for imaging neuroinflammation show promise

Read More

Sunovion files IND for second compound from drug discovery collaboration with PsychoGenics

Read More

OSE Immunotherapeutics collaborates with Memorial Sloan Kettering on OSE-703

Read More

Carma Therapeutics closes initial financing

Read More

DSMB recommends continuation of NASH-CX trial of GR-MD-02

Read More

FDA awards fast track designation to tanezumab for chronic pain indications

Read More

AbbVie and Principia Biopharma establish oral immunoproteasome inhibitor collaboration

Read More

[18F]FC-0324, a new PET tracer targeting cannabinoid CB2 receptors

Read More

Zafgen details results from first-in-human trial of obesity candidate ZGN-1061

Read More

Jiangsu Chia Tai Tianqing Pharmaceutical Group presents ALK inhibitors

Read More

Moleculin Biotech starts IND preparation for WP-1220 for CTCL

Read More

Leo Pharma patents 3-triazolo-3-deoxy-ingenol derivatives

Read More

AbbVie discovers 5-HT2C receptor agonists

Read More

Pulmatrix in-licenses RespiVert kinase inhibitors

Read More

Ohara Pharmaceutical discloses prodrugs of azacytidine and decitabine

Read More

Genentech and Xenon Pharmaceuticals disclose Nav1.7 channel blockers

Read More

Grant supports BrainStorm Cell Therapeutics' development of NurOwn

Read More

Galapagos compound GLPG-1690 given U.S. orphan designation for idiopathic pulmonary fibrosis

Read More

NCI grant supports continued research at Case Western on Barrett's esophagus

Read More

[18F]GE-180 evaluated in patients with high grade glioma and multiple sclerosis

Read More

AbbVie drug receives FDA orphan status for onchocerciasis and lymphatic filariasis

Read More

IT-139 named a U.S. orphan drug for pancreatic cancer

Read More

FDA grants breakthrough therapy designation for OMS-721 in IgA nephropathy

Read More

Phase III trial of Bronchitol in cystic fibrosis meets primary endpoint

Read More

Cellth Systems granted rights to CTC cell-tethering technology

Read More

Repurposed cancer drug SU-9516 may have potential for Duchenne muscular dystrophy

Read More

FDA issues 510(k) clearance for Techlab's E. Histolytica Quik Chek test

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing